GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Certara Inc (NAS:CERT) » Definitions » ROE %

Certara (Certara) ROE % : -4.75% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Certara ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Certara's annualized net income for the quarter that ended in Dec. 2023 was $-49.8 Mil. Certara's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $1,049.3 Mil. Therefore, Certara's annualized ROE % for the quarter that ended in Dec. 2023 was -4.75%.

The historical rank and industry rank for Certara's ROE % or its related term are showing as below:

CERT' s ROE % Range Over the Past 10 Years
Min: -7.52   Med: -3.51   Max: 1.39
Current: -5.16

During the past 6 years, Certara's highest ROE % was 1.39%. The lowest was -7.52%. And the median was -3.51%.

CERT's ROE % is ranked worse than
67.32% of 612 companies
in the Healthcare Providers & Services industry
Industry Median: 4.035 vs CERT: -5.16

Certara ROE % Historical Data

The historical data trend for Certara's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Certara ROE % Chart

Certara Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -1.81 -7.52 -1.42 1.39 -5.21

Certara Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.44 0.50 1.73 -18.23 -4.75

Competitive Comparison of Certara's ROE %

For the Health Information Services subindustry, Certara's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Certara's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Certara's ROE % distribution charts can be found below:

* The bar in red indicates where Certara's ROE % falls into.



Certara ROE % Calculation

Certara's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-55.357/( (1079.661+1046.84)/ 2 )
=-55.357/1063.2505
=-5.21 %

Certara's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-49.824/( (1051.751+1046.84)/ 2 )
=-49.824/1049.2955
=-4.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Certara  (NAS:CERT) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-49.824/1049.2955
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-49.824 / 352.04)*(352.04 / 1544.9805)*(1544.9805 / 1049.2955)
=Net Margin %*Asset Turnover*Equity Multiplier
=-14.15 %*0.2279*1.4724
=ROA %*Equity Multiplier
=-3.22 %*1.4724
=-4.75 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-49.824/1049.2955
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-49.824 / -49.536) * (-49.536 / -33.868) * (-33.868 / 352.04) * (352.04 / 1544.9805) * (1544.9805 / 1049.2955)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0058 * 1.4626 * -9.62 % * 0.2279 * 1.4724
=-4.75 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Certara ROE % Related Terms

Thank you for viewing the detailed overview of Certara's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Certara (Certara) Business Description

Traded in Other Exchanges
N/A
Address
100 Overlook Center, Suite 101, Princeton, NJ, USA, 08540
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The group has a business presence in the United States, EMEA, and other regions, of which a majority of revenue is derived from the United States.
Executives
Richard M. Traynor officer: See Remarks 1114 AVENUE OF THE AMERICAS, 45TH FLOOR, NEW YORK NY 10036
Leif E Pedersen officer: President, Software 10188 TELESIS COURT, SUITE 100, SAN DIEGO CA 92121
Eran Broshy director C/O VENTIV HEALTH, 200 COTTONTAIL LN. VANTAGE COURT N., SOMERSET NJ 08873
Patrick F Smith officer: PRESIDENT, INTEGRATED DRUG DEV C/O CERTARA, INC., 100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
John E Gallagher officer: CHIEF FINANCIAL OFFICER BECTON, DICKINSON AND COMPANY, FRANKLIN LAKES NJ 07417
Arsenal Saturn Holdings Lp 10 percent owner C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Jeffrey B. Kovach 10 percent owner C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Partners Iii-b Lp 10 percent owner 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Terrence M. Mullen 10 percent owner C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Eqt Avatar Parent L.p. 10 percent owner 100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Arsenal Capital Investment Iii Lp 10 percent owner C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Investment Vi Lp 10 percent owner C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Partners Iii Lp 10 percent owner 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
David Spaight director 100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Mason P Slaine director 2777 SUMMER STREET, SUITE 209, STAMFORD CT 06905